Payment overview · 2025
General Payments
$928.51
49 reported records · 15 companies
Healthcare provider profile · identity verified
Michael Frank Lurakis, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MAYS LANDING, NJ · NPI 1437228178
Verified facts
What the public records show
CMS Open Payments records show Michael Frank Lurakis, D.O. received $928.51 in general payments during 2025 across 49 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $205.50 | 22.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.74 | 16.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.33 | 9.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.54 | 7.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.22 | 7.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.47 | 6.2% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $50.02 | 5.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.41 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.47 | 3.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.87 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.37 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.43 | 3.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.88 | 3.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.95 | 2.3% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.31 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $928.51 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $205.50 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $169.33 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.27 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $50.02 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $42.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.88 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 736 | 235 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 107 |
| Ramipril | Ramipril | 313 | 97 |
| Ezetimibe | Ezetimibe | 259 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 81 |
| Omeprazole | Omeprazole | 214 | 73 |
| Metformin Hcl | Metformin Hcl | 210 | 63 |
| Losartan Potassium | Losartan Potassium | 208 | 73 |
| Lisinopril | Lisinopril | 177 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 52 |
| Alprazolam | Alprazolam | 150 | 33 |
| Carvedilol | Carvedilol | 134 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 42 |
| Montelukast Sodium | Montelukast Sodium | 122 | 41 |
| Alendronate Sodium | Alendronate Sodium | 119 | 38 |
| Famotidine | Famotidine | 109 | 32 |
| Furosemide | Furosemide | 109 | 33 |
| Eliquis | Apixaban | 94 | 24 |
| Gabapentin | Gabapentin | 94 | 41 |
| Tramadol Hcl | Tramadol Hcl | 91 | 18 |
| Synthroid | Levothyroxine Sodium | 90 | 23 |
| Allopurinol | Allopurinol | 85 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 36 |
| Raloxifene Hcl | Raloxifene Hcl | 81 | 25 |
| Potassium Chloride | Potassium Chloride | 77 | 29 |
| Jardiance | Empagliflozin | 75 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 30 |
| Sertraline Hcl | Sertraline Hcl | 67 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 18 |
| Finasteride | Finasteride | 59 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 11 |
| Farxiga | Dapagliflozin Propanediol | 56 | 18 |
| Trazodone Hcl | Trazodone Hcl | 56 | 25 |
| Chlorthalidone | Chlorthalidone | 54 | 20 |
| Terazosin Hcl | Terazosin Hcl | 50 | suppressed |
| Glimepiride | Glimepiride | 48 | 15 |
| Januvia | Sitagliptin Phosphate | 48 | 15 |
| Atenolol | Atenolol | 47 | 15 |
| Doxepin Hcl | Doxepin Hcl | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 15 |
| Celecoxib | Celecoxib | 42 | 15 |
| Ozempic | Semaglutide | 42 | 15 |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Telmisartan | Telmisartan | 41 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 40 | 11 |
| Spironolactone | Spironolactone | 39 | 11 |
| Ibuprofen | Ibuprofen | 38 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 14 |
| Myrbetriq | Mirabegron | 34 | 13 |
| Invokana | Canagliflozin | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 14 |
| Valsartan | Valsartan | 33 | 11 |
| Simvastatin | Simvastatin | 32 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $928.51 · 49 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, RECORLEV, REPATHA, Rybelsus, UPTRAVI, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error